Acknowledgments
Alan Tomlinson, Department of Optometry, Glasgow Caledonian University, Glasgow, U.K. for advice on pathophysiology of contact lens wear over many years (Chapter 6 and Appendix D) and Acanthamoeba.
Consuelo Ferrer ,Vissum, Alicante, Spain for assistance with molecular biology (Chapter 3) and advice with Appendix D and for photomicrographs of Fusarium. Jorge Alio, Chief Ophthalmologist, Vissum, Alicante, Spain for supplying photos of fungal keratitis and for much useful discussion on causes and prevention of postoperative endopthalmitis.
David Lloyd, Renaissance Healthcare, Epsom, U.K. and Klaus Geldsetzer, Santen gmbh Munich, Germany for pharmaceutical advice and for assistance with Chapter 4 and Appendices C and D.
Gholam Peyman, Department of Ophthalmology, University of Tucson, Arizona, U.S.A.; Kirk Wilhelmus, Cullen Eye Institute, Baylor College of Medicine, Houston, Texas, U.S.A.; Steven Barrett, Charing Cross Hospital, London U.K.; Crawford Revie and George Gettinby, Department of Modelling Science, University of Strathclyde, Glasgow U.K.; Peter Barry, Department of Ophthalmology, St. Vincent’s Hospital, Dublin, Eire; Per Montan, Department of Ophthalmology, St. Erik’s Hospital, Gothenburg, Sweden; Gunther Grabner, Department of Ophthalmology, University Hospital, Salzburg, Austria; Luis Cordoves, Department of Ophthalmology, University Hospital, Tenerife, Canary Islands, Spain; Christopher Lowman and Udo Reischl, Departments of Ophthalmology and Molecular Biology, University of Regensburg, Regensburg, Germany; Marie-Jose Tassignon, Department of Ophthalmology, University Hospital, Antwerp, Belgium; Hugo Verbraeken, Department of Ophthalmology, University Hospital, Ghent, Belgium; Suleyman Kaynak, Department of Ophthalmology, University Hospital, Izmir, Turkey and colleagues in the ESCRS (European Society of Cataract & Refractive Surgeons) for their help, discussions, and advice with prophylaxis and management of post-operative endophthalmitis (Chapter 8).
John Hay, Glasgow, U.K. for his original construction of Table 1 in Appendix B and for drug information.
Magnus Peterson, Department of Modelling Science, University of Strathclyde, Glasgow U.K. for Tables 1–5 in Chapter 10 and good advice.
Philip Thomas, Joseph Eye Hospital, Tiruchirrapalli, India for assistance with mycological methods (Chapter 2) and drugs (Appendix A) and Fusarium (Appendix D).
vii
viii Acknowledgments
Tara Beattie, Department of Civil Engineering (Public Health), University of Strathclyde, Glasgow U.K.; Andrew Rogerson, Marshall University, Huntington, West Virginia, U.S.A.; Megan Shoff, Department of Evolution, Ecology, and Organismal Biology, The Ohio State University, Columbus, Ohio U.S.A. and Scott Schatz, Department of Optometry, Nova SE University, Ft. Lauderdale, U.S.A. for many useful discussions on Acanthamoeba pathogenicity (Chapter 6).
We are also grateful for assistance by Jill Bloom, Senior Drug Information Pharmacist, Moorfields Eye Hospital, London, U.K. and by members of Bausch & Lomb, Kingston, London U.K. for helpful discussions with Appendix C.
Finally, we are most grateful to Alan Burgess, Informa U.K. and for the general assistance of publishing staff of Informa U.S.A.
Contents
Preface to the Second Edition |
iii |
Preface to the First Edition |
v |
Acknowledgements vii |
|
Contributors xi |
|
n |
Pathogenesis of Infection and the Ocular Immune Response |
1 |
||||||
1 |
||||||||
n |
Microbiology |
23 |
|
|
|
|
||
2 |
|
|
|
|
||||
n |
Molecular Biology |
61 |
|
|
|
|||
3 |
|
|
|
|||||
n |
Pharmacology and Pharmacokinetics 105 |
|
||||||
4 |
|
|||||||
n |
Cellulitis, Blepharitis, and Dacrocystitis 127 |
|
||||||
5 |
|
|||||||
n |
Conjunctiva, Cornea, and Anterior Chamber 139 |
|
||||||
6 |
|
|||||||
n |
Uvea and Retina |
191 |
|
|
|
|||
7 |
|
|
|
|||||
n |
Endophthalmitis Including Prevention and Trauma 239 |
|
||||||
8 |
|
|||||||
n |
Tropical Ophthalmomycoses |
271 |
|
|||||
9 |
|
|||||||
n |
Epidemiology |
307 |
|
|
|
|||
10 |
|
|
|
|||||
|
|
|||||||
APPENDIX A |
Modes of Delivery and Formulations of Antibiotics and |
|||||||
|
|
|
Antifungal Drugs |
323 |
|
|||
|
Protozoa, Helminths, and Arachnids: Ocular Disease and |
|||||||
APPENDIX B |
||||||||
|
|
|
Chemotherapy |
333 |
|
|||
|
|
345 |
||||||
APPENDIX C |
Prevention of Hospital-Acquired Ocular Infection |
|||||||
|
||||||||
APPENDIX D |
Contact Lens-Associated Keratitis, Fusarium, Disinfecting Solutions, |
|||||||
|
|
|
and Hygiene |
353 |
|
|
||
Index 367
ix
